Additionally, we found that NASH patients exhibited significantly elevated activation of FAK, indicated by the upregulated expression of p-FAKY576+Y577 and p-FAKY397 in liver specimens compared with the Non-steatosis participants (Supplementary Fig. 16a). The gene discussed is PTK2; the disease is metabolic dysfunction-associated steatohepatitis.